Manish A. Shah

发表

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline

J. Lacy, Z. Wainberg, T. Alcindor, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improving outcomes in patients with oesophageal cancer

A. Bass, N. Altorki, J. Abrams, 2023, Nature Reviews Clinical Oncology.

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

J. Ajani, Y. Bang, F. Lordick, 2023, The Lancet.

Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study

J. Ajani, Y. Bang, E. Van Cutsem, 2023, Journal of Clinical Oncology.

Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.

J. Ajani, P. Sunpaweravong, Y. Bang, 2023, Journal of Clinical Oncology.

198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

J. Ajani, Y. Bang, Ruifeng Xu, 2020 .

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer

G. Ku, M. Fakih, S. Krishnamurthi, 2023, Journal for ImmunoTherapy of Cancer.

The germline CDH1 c.48 G>C substitution contributes to cancer predisposition through generation of a pro-invasive mutation.

M. Shah, R. Seruca, Soraia Melo, 2014, Mutation research.

Abstract CT009: Phase II trial of perioperative pembrolizumab plus capecitabine and oxaliplatin followed by adjuvant pembrolizumab for resectable gastric and gastroesophageal junction (GC/GEJ) adenocarcinoma

Shing M. Lee, Haeseong Park, G. Manji, 2022, Cancer Research.

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study

Sung-Bae Kim, J. Lunceford, M. Shah, 2019, JAMA oncology.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

Laura H. Tang, M. Shah, Y. Janjigian, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent.

Cindy Chen, Scott W. Brown, Thomas R Campion, 2019, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.

Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases

M. Gonen, M. Shah, D. Klimstra, 2004, British Journal of Cancer.

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Sung-Bae Kim, M. Shah, F. Lordick, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

J. Ajani, P. Sunpaweravong, Y. Bang, 2023, Nature Medicine.